A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB

被引：0
|
作者：
Ajani, J. A. [1 ]
Udrea, A. [2 ]
Sarosiek, T. [3 ]
Shenker, M. [4 ]
Morgan, C. [5 ]
Pikiel, J. [6 ]
Wojcik, E. [7 ]
Swinson, D. [8 ]
Joseph, M. [9 ]
Luft, A. [10 ]
Salek, T. [11 ]
Tournigand, C. [12 ]
Ferry, D. [13 ]
Zhang, Y. [13 ]
Long, A. [13 ]
Kuo, W-L. [13 ]
Gao, L. [13 ]
Kauh, J. [13 ]
Mansoor, W. [14 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] MedisProf SRL, Oncol, Cluj Napoca, Romania
[3] Magodent, Oncol, Warsaw, Poland
[4] Sf Nectarie SRL, Ctr Oncol, Craiova, Romania
[5] Velindre Canc Ctr, Oncol, Cardiff, S Glam, Wales
[6] COPERNICUS Podmiot Leczniczy, Oncol, Gdansk, Poland
[7] NZOZ Ctr Med HCP, Oncol, Poznan, Poland
[8] St James Univ Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England
[9] New Cross Hosp, Deanesly Ctr, Wolverhampton, England
[10] Leningrad Reg Clin Hosp, Oncol, St Petersburg, Russia
[11] Narodny Onkol Ustav, Oncol, Bratislava, Slovakia
[12] CHU Henri Mondor, Oncol, Creteil, France
[13] Eli Lilly & Co, Oncol, Bridgewater, NJ USA
[14] NHS Fdn Trust, Christie Hosp, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
698P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4
    Janjigian, Y. Y.
    Lloyd, C.
    de Giorgio-Miller, V. G.
    Chang, Y-T.
    Lee, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1502 - S1503
  • [22] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study
    Shitara, K.
    Barlaskar, F.
    Franke, F.
    Kawaguchi, Y.
    Shen, L.
    Kamio, T.
    Meinhardt, G.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S306 - S307
  • [23] Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer
    Alsina, M.
    Ko, A. H.
    De Paredes, M. Garcia
    Rivera, F.
    Schwartzberg, L. S.
    Fattaey, A.
    Kunkel, L. A.
    Tabernero, J.
    Ajani, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] FG-M108 plus capecitabine and oxaliplatin (CAPOX) for first-line treatment of CLDN18.2+/HER2-advanced gastric/gastroesophageal junction adenocarcinoma (GC): Update results of a phase I/II trial to determine RP2D.
    Gong, Jifang
    Liu, Funan
    Jin, Zhaoyu
    Zhang, Miao
    Zhang, Shu
    Zhang, Yanqiao
    Liang, Xinjun
    Li, Yun
    Yang, Yaping
    Zhu, Lingyin
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [25] Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
    Shen, L.
    Chen, P.
    Lu, J.
    Wan, Y.
    Zheng, Y.
    Ye, F.
    Yang, J.
    Liu, Y.
    Pan, H.
    Chen, H.
    Sun, M.
    Fan, Q.
    Yuan, Y.
    Chen, K.
    Sun, Z.
    Tian, H.
    Ye, X.
    Peng, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S1542 - S1543
  • [26] HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
    Shah, Manish A.
    Xu, Rui-hua
    Bang, Yung-Jue
    Hoff, Paulo M.
    Liu, Tianshu
    Herraez-Baranda, Luis A.
    Xia, Fan
    Garg, Amit
    Shing, Mona
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) : 2558 - +
  • [27] HELOISE: phase IIIB randomized multicenter study comparing two trastuzumab (H) dose regimens combined with chemotherapy (CT) as first-line (1L) therapy in patients (pts) with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC)
    Shah, Manish A.
    Xu, Ruihua
    Bang, Yung-Jue
    Hoff, Paulo M.
    Liu, Tianshu
    Herraez-Baranda, Luis A.
    Xia, Fan
    Garg, Amit
    Shing, Mona
    Tabernero, Josep
    CANCER RESEARCH, 2016, 76
  • [28] Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
    Lee, Keun Wook
    Im, Young-Hyuck
    Lee, Keun Seok
    Cho, Jae Yong
    Oh, Do-Youn
    Chung, Hyun Cheol Cheol
    Chao, Yee
    Bai, Li-Yuan
    Yen, Chia Jui
    Kim, In-Ho
    Oh, Sang Cheul
    Lin, Chia-Chi
    Wang, Jin
    Wang, Xin
    Li, Huiyan
    Chen, Yen-Yang
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345